var data={"title":"Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/contributors\" class=\"contributor contributor_credentials\">Arnold S Freedman, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/contributors\" class=\"contributor contributor_credentials\">Jon C Aster, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/contributors\" class=\"contributor contributor_credentials\">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/contributors\" class=\"contributor contributor_credentials\">Alan G Rosmarin, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 19, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the World Health Organization classification system for hematologic malignancies, the lymphoblastic neoplasms, which may present as leukemia <span class=\"nowrap\">and/or</span> lymphoma, are divided into two general categories based upon lineage (see <a href=\"topic.htm?path=classification-of-the-hematopoietic-neoplasms\" class=\"medical medical_review\">&quot;Classification of the hematopoietic neoplasms&quot;</a>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/1,2\" class=\"abstract_t\">1,2</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Precursor B cell lymphoblastic <span class=\"nowrap\">leukemia/lymphoma,</span> also called precursor B cell acute lymphoblastic leukemia (precursor B cell ALL)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Precursor T cell lymphoblastic <span class=\"nowrap\">leukemia/lymphoma</span> (precursor T-LBL), also called precursor T cell acute lymphoblastic leukemia (precursor T cell ALL)</p><p/><p>This is largely done because the prognosis and treatment differ between neoplasms of B and T cell lineage. These can be further divided into either lymphoblastic lymphoma or lymphoblastic leukemia:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinically, a case is defined as lymphoma (LBL) if there is a mass lesion in the mediastinum or elsewhere and &lt;25 percent blasts in the bone marrow.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>It is classified as leukemia (ALL) if there are &gt;25 percent bone marrow blasts, with or without a mass lesion.</p><p/><p>Within each lineage group, there is significant biological and clinical overlap between neoplasms diagnosed as LBL and ALL. Although some patients present with predominantly lymphomatous involvement (eg, a mediastinal mass or another defined lesion), most have or later develop marrow involvement. Similarly, patients who present with leukemia may have or may develop extramedullary tumors. Accordingly, lymphoblastic lymphoma and acute lymphoblastic leukemia should be considered the same disease with different clinical presentations [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/3\" class=\"abstract_t\">3</a>].</p><p>The pathobiology, diagnosis, and clinical presentation of precursor B lymphoblastic <span class=\"nowrap\">leukemia/lymphoma</span> will be discussed here. The diagnosis of precursor T lymphoblastic <span class=\"nowrap\">leukemia/lymphoma</span> and the treatment of these disorders are discussed separately. (See <a href=\"topic.htm?path=induction-therapy-for-philadelphia-chromosome-negative-acute-lymphoblastic-leukemia-in-adults\" class=\"medical medical_review\">&quot;Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults&quot;</a> and <a href=\"topic.htm?path=general-principles-of-hematopoietic-cell-transplantation-for-acute-lymphoblastic-leukemia-in-adults\" class=\"medical medical_review\">&quot;General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">CELL OF ORIGIN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Precursor B-lymphoblastic <span class=\"nowrap\">leukemia/lymphoma,</span> also called precursor B cell acute lymphoblastic leukemia (precursor B cell ALL), is postulated to arise from precursor B cells at varying stages of differentiation. As with other forms of acute leukemia, in experimental systems only a small fraction of tumor cells appear to be able to establish disease in immunodeficient mice, suggesting that the tumor is maintained by a small number of leukemia initiating cells (so-called leukemia stem cells). Uncertainty remains regarding the precise identity of these cells, which may lie at the root of precursor <span class=\"nowrap\">B-ALL/LBL</span> and therefore be the key cells to target if patients are to be cured [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/4\" class=\"abstract_t\">4</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Precursor <span class=\"nowrap\">B-ALL/LBL</span> accounts for approximately 2 percent of the lymphoid neoplasms diagnosed in the United States [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/5\" class=\"abstract_t\">5</a>]. It occurs most frequently in childhood, but can also be seen in adults, with an overall median age in adults of 39 [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/6\" class=\"abstract_t\">6</a>]. In the United States, the incidence is approximately 11 cases per million persons per year [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/7\" class=\"abstract_t\">7</a>].</p><p>Precursor B-ALL occurs slightly more frequently in males than females, and three times as frequently in Whites as in Blacks [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/7\" class=\"abstract_t\">7</a>]. Hispanics have the highest incidence of any ethnic group. Incidence appears to be increased in certain areas of Central and South America (eg, Guatemala, Peru) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/8\" class=\"abstract_t\">8</a>]. The bases for these variations in incidence are unknown.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Precursor <span class=\"nowrap\">B-ALL/LBL</span> more frequently presents in its leukemic form (precursor B cell ALL) than its lymphomatous form (precursor B cell LBL). The disease tempo is variable with some patients presenting with symptoms progressing slowly over weeks to months and with others presenting more acutely.</p><p>Patients with precursor B cell ALL typically present with symptoms related to anemia, thrombocytopenia, and neutropenia due to replacement of the bone marrow with tumor. Symptoms can include fatigue, easy or spontaneous <span class=\"nowrap\">bruising/bleeding,</span> and infections. B-symptoms, such as fever, night sweats, and unintentional weight loss are often present, but may be mild. Hepatomegaly, splenomegaly, and lymphadenopathy can be seen in up to half of adults on presentation. Central nervous system (CNS) involvement is common and can be accompanied by cranial neuropathies or symptoms, predominantly meningeal, related to increased intracranial pressure.</p><p>By definition, patients with precursor B cell LBL present with a mass lesion and have &lt;25 percent blasts in the bone marrow. Unlike precursor T cell LBL, mediastinal masses are rare but lymph nodes and extranodal sites, such as the bone and the skin, are more frequently involved [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/9\" class=\"abstract_t\">9</a>]. A study of 53 children with B cell LBL enrolled on three prospective trials reported the following areas as the main location of disease at the time of diagnosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/10\" class=\"abstract_t\">10</a>]: osteolytic bone lesions (26 percent), skin or subcutaneous lesions (23 percent), mediastinal or pleural disease (11 percent), bone marrow (13 percent), lymph nodes alone (13 percent), gonads (6 percent), head and neck (4 percent), or kidney and digestive system (2 percent each). Upon further evaluation, 43 percent had bone marrow involvement and 6 percent had CNS involvement at diagnosis.</p><p class=\"headingAnchor\" id=\"H498317\"><span class=\"h1\">PATHOLOGIC FEATURES</span></p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Morphology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>On peripheral blood smears, lymphoblasts vary from small cells with scant cytoplasm, condensed nuclear chromatin, and indistinct nucleoli to larger cells with moderate amounts of cytoplasm, dispersed chromatin, and multiple nucleoli (<a href=\"image.htm?imageKey=HEME%2F83240\" class=\"graphic graphic_picture graphicRef83240 \">picture 1</a>). A few azurophilic cytoplasmic granules may be present. Auer rods are absent.</p><p>In tissue sections, the tumor cells are small to medium-sized, with scant cytoplasm, round, oval, or convoluted nuclei, fine chromatin and indistinct or small nucleoli (<a href=\"image.htm?imageKey=HEME%2F83239\" class=\"graphic graphic_picture graphicRef83239 \">picture 2</a> and <a href=\"image.htm?imageKey=HEME%2F83241\" class=\"graphic graphic_picture graphicRef83241 \">picture 3</a>). Occasional cases have larger cells. Precursor B <span class=\"nowrap\">LBL/ALL</span> is morphologically indistinguishable from precursor T <span class=\"nowrap\">ALL/LBL</span>.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Histochemistry and immunophenotype</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Evaluation often includes both histochemistry and flow cytometry, the latter being more informative. On histochemistry, the blasts often show &quot;chunky&quot; positivity on periodic acid Schiff (PAS) staining, variable positivity for nonspecific esterase and sudan black B, and universal negativity for myeloperoxidase.</p><p>Of greater importance is characterization with antibody stains, which are usually carried out by flow cytometry (<a href=\"image.htm?imageKey=HEME%2F83238\" class=\"graphic graphic_figure graphicRef83238 \">figure 1</a>). The blasts are virtually always positive for terminal deoxytransferase (TdT) (<a href=\"image.htm?imageKey=HEME%2F83237\" class=\"graphic graphic_picture graphicRef83237 \">picture 4</a>) and variably express the B cell markers CD19, CD22, CD20 and CD79a, leukocyte common antigen CD45 and common acute lymphoblastic leukemia antigen CD10 (CALLA). T cell markers such as CD3 are negative.</p><p>The constellation of antigens identified defines the stage of differentiation, ranging from (earliest to latest):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Early precursor B (pro-B-ALL) &ndash; membrane CD19+, CD79a+, and cytoplasmic CD22+</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Common ALL &ndash; CD10+</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Late pre-B ALL &ndash; CD20+, cytoplasmic mu heavy chain</p><p/><p>Approximately 40 percent of cases will express the lineage-independent stem cell antigen CD34.</p><p>Co-expression of myeloid antigens is seen in up to 30 percent of cases, most commonly CD13 (14 percent) <span class=\"nowrap\">and/or</span> CD33 (16 percent) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/11,12\" class=\"abstract_t\">11,12</a>]. Expression of CD13 and CD33 is associated with the presence of rearrangements involving the ETV6 gene (previously called TEL), usually as part of a t(12;21)(p12;q22) that creates an ETV6-CBFA2 (or TEL-AML1) fusion gene. Co-expression of CD68, CD15, and CD33 is often seen in cases with rearrangements involving the MLL gene, such as t(4;11) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/12\" class=\"abstract_t\">12</a>]. (See <a href=\"topic.htm?path=cytogenetics-and-molecular-genetics-in-acute-lymphoblastic-leukemia\" class=\"medical medical_review\">&quot;Cytogenetics and molecular genetics in acute lymphoblastic leukemia&quot;</a> and <a href=\"#H7\" class=\"local\">'Genetic features'</a> below.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Genetic features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rearrangement of antigen receptor genes is variable in lymphoblastic neoplasms, and may not be lineage-specific; thus, precursor B cell neoplasms may have either or both immunoglobulin heavy chain and T cell receptor gamma or beta chain gene rearrangements, or may lack rearrangements [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/13-15\" class=\"abstract_t\">13-15</a>]. As such, we rely upon an analysis of immunophenotype to designate T cell or B cell lineage.</p><p>Chromosomal abnormalities are common in precursor-B lymphoblastic neoplasms. Although not specifically used in the diagnosis of precursor B cell <span class=\"nowrap\">LBL/ALL,</span> they are important for prognosis. They are typically divided into numerical changes and translocations. Also important are certain point mutations. These are discussed in the following sections.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Numerical changes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Numerical changes in chromosomes include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hyperdiploidy &gt;50 chromosomes</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypodiploidy &lt;45 chromosomes</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><span class=\"nowrap\">Pseudodiploidy/translocations</span></p><p/><p>The frequency of these abnormalities varies between children and adults, and some are associated with characteristic immunophenotypes <span class=\"nowrap\">and/or</span> clinical behavior.</p><p>Hyperdiploidy (51 to 65 chromosomes; DNA index 1.16-1.6) is seen in up to 50 percent of cases of childhood precursor B-ALL and is associated with a good prognosis, particularly those with trisomies of chromosomes 4, 10, 17 and 18. This is due in part because of its association with the t(12;21), which is the most common translocation in childhood B-ALL. Both abnormalities are much less common in adult ALL.</p><p>Hypodiploidy (less than 45 chromosomes) is uncommon, occurring in around 1 percent of B-ALL in children and adolescents, and is associated with poor event-free survival and overall outcome [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/16\" class=\"abstract_t\">16</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h3\">Translocations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Many different translocations have been reported in B-ALL, three of which are clearly associated with treatment failure or success when using intensive chemotherapy. These include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The Philadelphia chromosome: t(9;22)(q34;q11); <em><span class=\"nowrap\">BCR/ABL1:</em></span> historically associated with a poor prognosis, this is the most frequent rearrangement in adult ALL. It is present in 25 percent of adult and 3 percent of childhood cases. The incidence of t(9;22) increases with age and is present in 40 to 50 percent of patients older than 60 years. A high fraction of Philadelphia chromosome positive B-ALLs are associated with loss of function mutations in Ikaros (encoded by the <em>IKZF1</em>) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/17\" class=\"abstract_t\">17</a>], a transcriptional repressor that regulates lymphoid development. Outcomes in <em><span class=\"nowrap\">BCR/ABL1</em>+</span> B-ALL has improved significantly with the addition of ABL tyrosine kinase inhibitors to therapeutic regimens [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/18\" class=\"abstract_t\">18</a>]. Of interest, a subset of B-ALL with Ikaros mutations that lacks the Philadelphia chromosome has also been described; these continue to be associated with a very poor prognosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/19\" class=\"abstract_t\">19</a>]. (See <a href=\"topic.htm?path=cytogenetics-and-molecular-genetics-in-acute-lymphoblastic-leukemia#H5\" class=\"medical medical_review\">&quot;Cytogenetics and molecular genetics in acute lymphoblastic leukemia&quot;, section on '4;11 translocation'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>t(v;11q23); <em>KMT2A</em> (formerly known as <em>MLL</em>) rearranged: associated with a poor prognosis, seen in infants &lt;1 year and adults [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/20\" class=\"abstract_t\">20</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>t(12;21)(p12;q22) <em>ETV6-RUNX1</em> (formerly known as <em><span class=\"nowrap\">TEL/AML1</em>):</span> associated with a good prognosis and hyperdiploidy, this is the most common rearrangement seen in children [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/21\" class=\"abstract_t\">21</a>].</p><p/><p>The t(9;22) and t(v;11q23) are often associated with a pro-B immunophenotype and a poor prognosis [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/11,20\" class=\"abstract_t\">11,20</a>], while the t(12;21) is associated with common pre-B ALL. Reports have also described a cryptic t(X;14) involving the IgH locus and the cytokine receptor gene <em>CRLF2</em> that is also associated with <em>IKZF1</em> mutations and a poor outcome [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/22\" class=\"abstract_t\">22</a>]. A more detailed discussion of chromosomal abnormalities in ALL is presented separately. (See <a href=\"topic.htm?path=cytogenetics-and-molecular-genetics-in-acute-lymphoblastic-leukemia\" class=\"medical medical_review\">&quot;Cytogenetics and molecular genetics in acute lymphoblastic leukemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2209446903\"><span class=\"h3\">Point mutations and small indels</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As already mentioned, mutations that disrupt <em>IKZF1</em>, which encodes the transcription factor Ikaros, are associated with poor outcomes [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/19\" class=\"abstract_t\">19</a>]. These generally consist of small deletions that lead to production of <em>IKZF1</em> splice variants with dominant negative activity. Mutations that disrupt <em>TP53</em> are found in 10 to 15 percent of B-ALL and are associated with hypodiploidy and a dismal prognosis, particularly if they are associated with deletion of the other <em>TP53</em> allele on chromosome 17q [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/23,24\" class=\"abstract_t\">23,24</a>].</p><p class=\"headingAnchor\" id=\"H102307411\"><span class=\"h3\">Gene expression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately 10 percent of childhood B-ALL and 25 percent of adult B-ALL are associated with a gene expression signature resembling that seen in Philadelphia chromosome positive B-ALL [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/25\" class=\"abstract_t\">25</a>]. Many of these tumors are <em>BCR-ABL1</em> positive, but others have one or another of a diverse collection of gene rearrangements that produce hyperactivity in other tyrosine kinases (eg, the erythropoietin receptor or JAK kinases) or cytokine signaling proteins (eg, CRLF2). Like the presence of <em>BCR-ABL1</em> fusion genes, this signature is associated with a poor outcome, but many of the underlying signaling abnormalities are potentially targetable with kinase inhibitors. Clinical trials are being designed to test the efficacy of such targeted therapeutics. (See <a href=\"topic.htm?path=cytogenetics-and-molecular-genetics-in-acute-lymphoblastic-leukemia#H73697009\" class=\"medical medical_review\">&quot;Cytogenetics and molecular genetics in acute lymphoblastic leukemia&quot;, section on 'BCR-ABL1-like B cell ALL'</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of precursor B-lymphoblastic <span class=\"nowrap\">leukemia/lymphoma</span> is made based upon the results of a bone marrow aspirate with or without biopsy, and aspirate with or without biopsy of other involved tissues, such as lymph nodes or skin. In addition to histological analysis, portions of the aspirated material should be sent for flow cytometry and cytogenetic evaluation.</p><p>It is essential to find blasts in the peripheral blood, bone marrow, or tissue biopsy. Their morphology varies, but is identical in precursor B <span class=\"nowrap\">LBL/ALL</span> and precursor T <span class=\"nowrap\">ALL/LBL</span>. In some instances, the blasts are so undifferentiated that morphologic distinction from acute myeloid leukemia (AML) is difficult or impossible. Because antigen receptor gene rearrangements are not entirely lineage specific, immunophenotype plays a key role in the diagnosis of precursor B <span class=\"nowrap\">LBL/ALL</span>.</p><p>Precursor B cell <span class=\"nowrap\">LBL/ALL</span> (like precursor T cell <span class=\"nowrap\">LBL/ALL)</span> is distinguished from AML by its positivity for TdT and lack of staining for myeloperoxidase. The B cell lineage is then identified by expression of B cell antigens (eg, CD19, CD22, CD20 and CD79a) and lack of expression of T cell antigens (eg, CD3). In more primitive precursor B cell <span class=\"nowrap\">LBL/ALLs,</span> CD19 may be the only B lineage marker present, whereas more mature tumors tend to express CD20. Surface immunoglobulin, the hallmark of a mature B cell, is absent, but cytoplasmic Ig mu heavy chain may be detected in more mature tumors.</p><p>The term precursor B cell acute lymphoblastic leukemia (B-ALL) is used if there are &gt;25 percent bone marrow blasts, with or without a mass lesion. For cases with a mass lesion and less than 25 percent bone marrow involvement, the term precursor B cell lymphoblastic lymphoma (B-LBL) is used.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Precursor B cell <span class=\"nowrap\">LBL/ALL</span> must be differentiated from other forms of lymphoma and leukemia and from the presence of increased numbers of normal maturing B cell precursors, known as hematogones. Most notably, precursor B cell <span class=\"nowrap\">LBL/ALL</span> is differentiated from precursor T cell <span class=\"nowrap\">LBL/ALL</span> by immunophenotypic analysis, which demonstrates B cell antigens and the absence of T cell antigens. In addition, precursor B and T cell <span class=\"nowrap\">LBL/ALL</span> are differentiated from AML by their positivity for TdT and lack of staining for myeloperoxidase. Although hematogones may be suggested by findings on immunohistochemical staining of bone marrow biopsy specimens [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/26\" class=\"abstract_t\">26</a>], they can be most easily distinguished from precursor B cell <span class=\"nowrap\">LBL/ALL</span> by multicolor flow cytometry [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/27\" class=\"abstract_t\">27</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-t-cell-acute-lymphoblastic-leukemia-lymphoma\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-acute-myeloid-leukemia\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Both tumor and patient characteristics can be used to predict treatment outcomes in precursor B cell <span class=\"nowrap\">ALL/LBL</span>. In particular, age at diagnosis and <span class=\"nowrap\">cytogenetic/genetic</span> findings appear to be the strongest predictors of survival. As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The outcome is less favorable in infants less than one year of age and in adults and more favorable in children.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In infants, many cases have translocations involving the <em>KMT2A</em> (<em>MLL</em>) gene at 11q23, which is associated with a poor prognosis at any age [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/20\" class=\"abstract_t\">20</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adult precursor B-ALL is more often associated with the poor-prognosis t(9;22) or t(v11q23) abnormalities, and survival is poorer than in childhood cases [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/11,28\" class=\"abstract_t\">11,28</a>]. Other poor prognostic factors include hypodiploidy, <em>IKZF1</em> mutations, and an expression signature resembling that associated with t(9;22)-positive cases. (See <a href=\"topic.htm?path=cytogenetics-and-molecular-genetics-in-acute-lymphoblastic-leukemia#H73697009\" class=\"medical medical_review\">&quot;Cytogenetics and molecular genetics in acute lymphoblastic leukemia&quot;, section on 'BCR-ABL1-like B cell ALL'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Older children more often have hyperdiploidy and the t(12;21), which confer a better prognosis (85 to 90 percent long-term survival) [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/21\" class=\"abstract_t\">21</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Myeloid antigen expression does not seem to be an independent prognostic factor in ALL [<a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/12,29\" class=\"abstract_t\">12,29</a>]. Overall, the prognosis for these patients may be worse than that for adults with T cell <span class=\"nowrap\">LBL/ALL</span>.</p><p/><p>While not yet routine, all acute leukemias seen at our institution are subjected to analysis using a targeted next-generation sequencing platform that covers certain genes that are prognostically important, such as <em>IKZF1</em> and <em>TP53</em>. </p><p>The relationship between prognosis and cytogenetic abnormalities in ALL is discussed in more detail elsewhere. (See <a href=\"#H7\" class=\"local\">'Genetic features'</a> above and <a href=\"topic.htm?path=cytogenetics-and-molecular-genetics-in-acute-lymphoblastic-leukemia\" class=\"medical medical_review\">&quot;Cytogenetics and molecular genetics in acute lymphoblastic leukemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=acute-lymphoblastic-leukemia-all-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Acute lymphoblastic leukemia (ALL) (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=acute-lymphoblastic-leukemia-all-treatment-in-adults-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Precursor B-lymphoblastic <span class=\"nowrap\">leukemia/lymphoma,</span> also called precursor B cell acute lymphoblastic leukemia (precursor B cell ALL) is postulated to arise from precursor B cells at varying stages of differentiation.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The term precursor B cell acute lymphoblastic leukemia (B-ALL) is used if there are &gt;25 percent bone marrow blasts, with or without a mass lesion. For cases with a mass lesion and less than 25 percent bone marrow involvement, the term precursor B cell lymphoblastic lymphoma (B-LBL) is used. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-t-cell-acute-lymphoblastic-leukemia-lymphoma#H733536\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma&quot;, section on 'Introduction'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Precursor <span class=\"nowrap\">B-ALL/LBL,</span> which accounts for approximately 2 percent of the lymphoid neoplasms, occurs most frequently in childhood, but can also be seen in adults. (See <a href=\"#H3\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Peripheral blood smear, bone marrow biopsy, and tissue biopsy can demonstrate lymphoblasts with varying morphology. Precursor B <span class=\"nowrap\">LBL/ALL</span> is morphologically indistinguishable from precursor T <span class=\"nowrap\">ALL/LBL</span>. (See <a href=\"#H5\" class=\"local\">'Morphology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Key diagnostic studies include histochemical stains, immunocytochemistry, and flow cytometry. These are required to differentiate between precursor <span class=\"nowrap\">B-ALL/LBL,</span> precursor <span class=\"nowrap\">T-ALL/LBL,</span> and other acute leukemias. (See <a href=\"#H6\" class=\"local\">'Histochemistry and immunophenotype'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although not specifically used in the diagnosis of precursor B cell <span class=\"nowrap\">LBL/ALL,</span> cytogenetic analysis is of prognostic importance in B lineage tumors. Some centers screen for <em>IKZF1</em> mutations, which confer a poor prognosis. Tests are under development that will permit identification of tumors with gene expression signatures that confer a worse prognosis. (See <a href=\"#H7\" class=\"local\">'Genetic features'</a> above and <a href=\"topic.htm?path=cytogenetics-and-molecular-genetics-in-acute-lymphoblastic-leukemia\" class=\"medical medical_review\">&quot;Cytogenetics and molecular genetics in acute lymphoblastic leukemia&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of precursor B-lymphoblastic <span class=\"nowrap\">leukemia/lymphoma</span> is made based upon the results of a bone marrow biopsy with or without biopsy of other involved tissues, such as lymph nodes or skin. (See <a href=\"#H10\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Both tumor and patient characteristics can be used to predict treatment outcomes in precursor B cell <span class=\"nowrap\">ALL/LBL</span>. In particular, age at diagnosis and chromosomal changes appear to be the strongest predictors of survival. (See <a href=\"#H12\" class=\"local\">'Prognosis'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.</li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/2\" class=\"nounderline abstract_t\">Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/3\" class=\"nounderline abstract_t\">Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/4\" class=\"nounderline abstract_t\">Bernt KM, Armstrong SA. Leukemia stem cells and human acute lymphoblastic leukemia. Semin Hematol 2009; 46:33.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/5\" class=\"nounderline abstract_t\">Han X, Kilfoy B, Zheng T, et al. Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control 2008; 19:841.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/6\" class=\"nounderline abstract_t\">Soslow RA, Baergen RN, Warnke RA. B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology. Cancer 1999; 85:2648.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/7\" class=\"nounderline abstract_t\">Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012; 119:34.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/8\" class=\"nounderline abstract_t\">Laurini JA, Perry AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 2012; 120:4795.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/9\" class=\"nounderline abstract_t\">Shafer D, Wu H, Al-Saleem T, et al. Cutaneous precursor B-cell lymphoblastic lymphoma in 2 adult patients: clinicopathologic and molecular cytogenetic studies with a review of the literature. Arch Dermatol 2008; 144:1155.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/10\" class=\"nounderline abstract_t\">Ducassou S, Ferlay C, Bergeron C, et al. Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951. Br J Haematol 2011; 152:441.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/11\" class=\"nounderline abstract_t\">Khalidi HS, Chang KL, Medeiros LJ, et al. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. Am J Clin Pathol 1999; 111:467.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/12\" class=\"nounderline abstract_t\">Pui CH, Rubnitz JE, Hancock ML, et al. Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia. J Clin Oncol 1998; 16:3768.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/13\" class=\"nounderline abstract_t\">Kitchingman GR, Rovigatti U, Mauer AM, et al. Rearrangement of immunoglobulin heavy chain genes in T cell acute lymphoblastic leukemia. Blood 1985; 65:725.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/14\" class=\"nounderline abstract_t\">Tawa A, Hozumi N, Minden M, et al. Rearrangement of the T-cell receptor beta-chain gene in non-T-cell, non-B-cell acute lymphoblastic leukemia of childhood. N Engl J Med 1985; 313:1033.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/15\" class=\"nounderline abstract_t\">Felix CA, Poplack DG, Reaman GH, et al. Characterization of immunoglobulin and T-cell receptor gene patterns in B-cell precursor acute lymphoblastic leukemia of childhood. J Clin Oncol 1990; 8:431.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/16\" class=\"nounderline abstract_t\">Nachman JB, Heerema NA, Sather H, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007; 110:1112.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/17\" class=\"nounderline abstract_t\">Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453:110.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/18\" class=\"nounderline abstract_t\">Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia 2014; 28:1467.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/19\" class=\"nounderline abstract_t\">Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360:470.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/20\" class=\"nounderline abstract_t\">Pui CH, Behm FG, Downing JR, et al. 11q23/MLL rearrangement confers a poor prognosis in infants with acute lymphoblastic leukemia. J Clin Oncol 1994; 12:909.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/21\" class=\"nounderline abstract_t\">Rubnitz JE, Pui CH, Downing JR. The role of TEL fusion genes in pediatric leukemias. Leukemia 1999; 13:6.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/22\" class=\"nounderline abstract_t\">Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010; 115:5312.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/23\" class=\"nounderline abstract_t\">Stengel A, Schnittger S, Weissmann S, et al. TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood 2014; 124:251.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/24\" class=\"nounderline abstract_t\">Forero-Castro M, Robledo C, Benito R, et al. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia. Br J Cancer 2017; 117:256.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/25\" class=\"nounderline abstract_t\">Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014; 371:1005.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/26\" class=\"nounderline abstract_t\">Al-Shieban S, Byrne E, Trivedi P, et al. Immunohistochemical distinction of haematogones from B lymphoblastic leukaemia/lymphoma or B-cell acute lymphoblastic leukaemia (B-ALL) on bone marrow trephine biopsies: a study on 62 patients. Br J Haematol 2011; 154:466.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/27\" class=\"nounderline abstract_t\">Kroft SH, Asplund SL, McKenna RW, Karandikar NJ. Haematogones in the peripheral blood of adults: a four-colour flow cytometry study of 102 patients. Br J Haematol 2004; 126:209.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/28\" class=\"nounderline abstract_t\">Boucheix C, David B, Sebban C, et al. Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Blood 1994; 84:1603.</a></li><li><a href=\"https://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-b-cell-acute-lymphoblastic-leukemia-lymphoma/abstract/29\" class=\"nounderline abstract_t\">Uckun FM, Sather HN, Gaynon PS, et al. Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 1997; 90:28.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4686 Version 19.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H22\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">CELL OF ORIGIN</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">EPIDEMIOLOGY</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">CLINICAL FEATURES</a></li><li><a href=\"#H498317\" id=\"outline-link-H498317\">PATHOLOGIC FEATURES</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">Morphology</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Histochemistry and immunophenotype</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Genetic features</a><ul><li><a href=\"#H8\" id=\"outline-link-H8\">- Numerical changes</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">- Translocations</a></li><li><a href=\"#H2209446903\" id=\"outline-link-H2209446903\">- Point mutations and small indels</a></li><li><a href=\"#H102307411\" id=\"outline-link-H102307411\">- Gene expression</a></li></ul></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">DIAGNOSIS</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">PROGNOSIS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H985266\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"HEME/4686|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/83238\" class=\"graphic graphic_figure\">- Flow B cell ALL</a></li></ul></li><li><div id=\"HEME/4686|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/83240\" class=\"graphic graphic_picture\">- Peripheral blood B cell ALL</a></li><li><a href=\"image.htm?imageKey=HEME/83239\" class=\"graphic graphic_picture\">- BM biopsy B cell ALL</a></li><li><a href=\"image.htm?imageKey=HEME/83241\" class=\"graphic graphic_picture\">- BM aspirate B cell ALL</a></li><li><a href=\"image.htm?imageKey=HEME/83237\" class=\"graphic graphic_picture\">- TdT staining ALL</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=classification-of-the-hematopoietic-neoplasms\" class=\"medical medical_review\">Classification of the hematopoietic neoplasms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-acute-myeloid-leukemia\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-precursor-t-cell-acute-lymphoblastic-leukemia-lymphoma\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cytogenetics-and-molecular-genetics-in-acute-lymphoblastic-leukemia\" class=\"medical medical_review\">Cytogenetics and molecular genetics in acute lymphoblastic leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-principles-of-hematopoietic-cell-transplantation-for-acute-lymphoblastic-leukemia-in-adults\" class=\"medical medical_review\">General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=induction-therapy-for-philadelphia-chromosome-negative-acute-lymphoblastic-leukemia-in-adults\" class=\"medical medical_review\">Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acute-lymphoblastic-leukemia-all-the-basics\" class=\"medical medical_basics\">Patient education: Acute lymphoblastic leukemia (ALL) (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acute-lymphoblastic-leukemia-all-treatment-in-adults-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)</a></li></ul></div></div>","javascript":null}